Tag: TargoPep

Global investment in gene therapeutics is on the rise, but are these investments on a sound footing?

With the increasing number of gene therapies hitting the market, this segment of the biotech industry must be approaching an inflection point and a related spurt in value growth…read our latest short article to find out more.

Scottish EDGE – finalist

Following a successful round in the Scottish EDGE entrepreneurship competition semi-final… TargoPep is thrilled to be going forward as a finalist!

Scottish EDGE – Semi-finalist!

We are thrilled to announce to our followers that TargoPep has been selected as finalist in the most recent Scottish Edge entrepreneurship competition.

How ‘Delivery Enabled’ oligotherapeutics can change the landscape of disease and treatment

Dr. Fergus McWhinnie, TargoPep’s CSO, looks at the story of oligotherapeutic approaches, the current success stories and the direction of research in the field that will provide future cures to today’s ‘uncurable’ diseases.

Introduction to TargoPep

CEO Ken Fyvie explains the origins of TargoPep and how it will enable the effective delivery of transformative next-generation gene therapies.

TargoPep enhances the successes of ‘Cell Penetrating Peptides’ to develop ‘Advanced Delivery Peptides’. But why did we do this?

Dr. Fergus McWhinnie writes about how and why Advanced Delivery Peptides have the potential to transform the delivery of life changing gene therapies to their site of action.

TargoPep presents at TIDES Europe

TargoPep made a brilliant impression at TIDES Europe in Amsterdam.

TargoPep pitches to the Scottish Investment Community at CONVERGE

TargoPep competes at the Innovation Showcase of the Converge challenge.